

Ref: GLL/BSE/2024-25/Feb-

Date: February 14, 2025

To  
The General Manager,  
Corporate Relations Department,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, **Mumbai – 400001**,  
Maharashtra State, India.  
**Script Code: 531739**

To  
The Listing Manager,  
**The Ahmedabad Stock Exchange Limited**  
A-2, Kamdhenu Complex, Opp. Sahajanand  
College, 120 Feet Ring Road, Panjara Pol,  
Ambawadi, **Ahmedabad - 380015**,  
Gujarat State, India.  
**Script Code:**

To  
**The Calcutta Stock Exchange  
Limited,**  
#7, Lyons Range, Murgighata,  
Dalhousie, **Kolkata - 700001**,  
West Bengal State, India.  
**Scrip Code: 26178**

Dear Sir/Madam,

**Sub: Statement of deviation or variation in the use of proceeds pursuant to Regulations 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. – Scrip Code: 531739/GENNEX**

Pursuant to Regulations 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that there is no deviation or variation in the use of the proceeds during the quarter ended December 31, 2024, from the objects stated in the letter of offer for the Funds raised by the Company. A statement of deviations, stating that there is no deviation or variation in the utilization of these proceeds, duly reviewed by the Audit Committee, is attached.

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours faithfully  
**For Gennex Laboratories Limited**

**Arihant Baid**  
Managing Director

## **Gennex Laboratories Limited**

## 1. FUND RAISED – RIGHT ISSUE

Name of the listed entity	GENNEX LABORATORIES LIMITED
Mode of funds raising	Rights Issues
Date of raising funds	26-08-2022
Amount raised	30.567 Crores
Report filed for the quarter ended	30-09-2024
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not applicable
Is there a deviation/variation in the use of funds raised	NO
If yes, whether the same is pursuant to change in terms of a contract or Not applicable objects, which was approved by the shareholders	Not applicable
If yes, date of shareholders approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	No comments
Comments of the Auditors, if any	No comments

## Gennex Laboratories Limited

## 2. FUND RAISED – PREFERENTIAL ISSUE

Name of the listed entity	GENNEX LABORATORIES LIMITED
Mode of funds raising	Preferential Issues
Date of raising funds	27-01-2024
Amount raised	73.75 Crores
Report filed for the quarter ended	30-09-2024
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not applicable
Is there a deviation/variation in the use of funds raised	NO
If yes, whether the same is pursuant to change in terms of a contract or Not applicable objects, which was approved by the shareholders	Not applicable
If yes, date of shareholders approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	No comments
Comments of the Auditors, if any	No comments

## Gennex Laboratories Limited

### **3. FUND RAISED – PREFERENTIAL ISSUE (CONVERTIBLE WARRANTS)**

Name of the listed entity	GENNEX LABORATORIES LIMITED
Mode of funds raising	Preferential Issues
Date of raising funds	27-01-2024
Amount raised	5.72 Crores
Report filed for the quarter ended	30-09-2024
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not applicable
Is there a deviation/variation in the use of funds raised	NO
If yes, whether the same is pursuant to change in terms of a contract or Not applicable objects, which was approved by the shareholders	Not applicable
If yes, date of shareholders approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	25% Application Money received against the 1,55,00,000 equity shares warrants @14.75, warrants will be converted within 18 months from the date of Allotment
Comments of the Auditors, if any	No comments

## **Gennex Laboratories Limited**